Skip to main content

Table 1 Demographics and characteristics for retreatment baseline

From: Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies

Characteristic HL patients ALCL patients
  (N = 21) (N = 8)
Age, year   
Median (range) 30 (16, 65) 51.5 (24, 72)
Gender, no. (%)   
Male 10 (48) 4 (50)
Female 11 (52) 4 (50)
Race, no. (%)   
Other 0 (0) 1 (13)
Black or African American 2 (10) 2 (25)
White 19 (90) 5 (63)
ECOG Performance Status, no. (%)   
0 8 (38) 3 (38)
1 12 (57) 4 (50)
2 1 (5) 1 (13)
Initial diagnosis, no. (%)   
ALK positive -- 3 (38)
ALK negative -- 5 (63)
Number of prior systemic therapiesa   
Median (range) 4 (2, 12) 3 (2, 6)
Time between last brentuximab vedotin dose on prior study and first dose of retreatment (months)   
Median (range) 11.4 (4, 45) 4.7 (2, 15)
Number of patients with intervening systemic therapies, n (%) 6 (21) 0
Best response, n/n (%)   
Stable disease 1 (17) --
Progressive disease 4 (67) --
Unknown/other 1 (17) --
Disease status relative to most recent prior therapy, n (%)   
Refractory 5 (24) 0
Relapse after response 16 (76) 8 (100)
  1. aIncludes any prior brentuximab vedotin treatment.